Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy

NCT03382795 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.

NCT NCT03382795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03382795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Retreatment With 1st Generation EGFR TKIs in Sensitizing EGFR Mutation Positive Non-Squamous Cell Carcinoma Patients Who Previously Treated With EGFR TKI and Cytotoxic Chemotherapy
Lead sponsor
Korea University Guro Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
January 3, 2018
Completion date
March 31, 2023
Enrollment
63 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

egfr positive non-small cell lung cancer